VERNON HILLS, Ill., Nov. 16 /PRNewswire-FirstCall/ -- Immtech International, Inc. announced today that its Board of Directors has appointed Eric L. Sorkin as the Chairperson of the Company’s Board of Directors. T. Stephen Thompson remains the Company’s President and Chief Executive Officer.
Mr. Sorkin, 46, has served the Company as a director since January 2000. He has over 24 years of experience in making and managing investments with particular expertise in acquisitions, transaction structuring and debt placement. He is a graduate of Yale University.
Mr. Sorkin stated, “This is an exciting time in Immtech’s growth path. We believe our first oral drug candidate is progressing successfully toward filing of an NDA and new drug candidates are getting ready to enter the pipeline. I look forward to working with the Immtech team as we ready to launch our first product and fill our pipeline with important new candidates.”
Stephen Thompson, President and CEO of Immtech International, stated, “Rick, in his new role as Chairman, will focus on enriching Immtech’s value by working closely with management and the Board of Directors to execute the Company’s strategy. In addition, Rick will assist in the development of a long-term plan to continue protecting and maximizing the Company’s growing intellectual property portfolio. Having Rick’s two plus decades of insight and expertise in management and as a strategic investor will be invaluable as the Company advances towards commercialization.”
The Company will hold a conference call on Wednesday, November 16, 2005 at 5:00 P.M. EST. The call will last for up to one hour. Investors and interested parties will have the opportunity to listen to and join in the call by calling 877-497-0736 and registering with the operator. Please call no later than 10 minutes prior to the start of the call to register. A replay of the conference call will be available for 30 days by dialing 877-497-0736 and entering 2638742.
About Immtech International
Immtech International, Inc. is a pharmaceutical company working to commercialize oral drugs to treat infectious diseases and aims to expand the targeted markets by applying its proprietary cation library of over 2300 well- defined compounds to the treatment of cancer, diabetes and other disorders. Immtech has advanced clinical programs that include new treatments for malaria, Pneumocystis pneumonia (“PCP”) and African sleeping sickness (trypanosomiasis), and drug development programs for fungal infections and tuberculosis. The Company has worldwide licensing and exclusive commercialization rights to an aromatic cationic pharmaceutical technology platform, from which a pipeline of drugs may be developed to serve the large, global markets. For additional information, please go to http://www.immtech-international.com.
“Safe Harbor” Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech International, Inc.'s business which are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report on Form 10-K for the most recently ended fiscal year.
Immtech International, Inc.
CONTACT: F. C. Thompson of Immtech International, Inc., 877-898-8038
Web site: http://www.immtech-international.com/
